Open AccessRecommendations for the Use of Prolonged‐Release Fampridine in Patients with Multiple Sclerosis ( MS )
Author(s) -
Preiningerova Jana Lizrova,
Baumhackl Ulf,
Csepany Tunde,
Czaplinski Adam,
Deisenhammer Florian,
Derfuss Tobias,
Fabjan Tanja H.,
Fazekas Franz,
Fuchs Siegrid,
Havrdova Eva,
Ledinek Alenka Horvath,
Illes Zsolt,
Jazbec Sasa Sega,
Klimova Eleonora,
Komoly Samuel,
Kurca Egon,
Linnebank Michael,
Lisy Lubomir,
Mares Jan,
Prochazkova Lubica,
Csilla Rozsa,
Szilasiova Jarmila,
Stourac Pavel,
Talab Radomir,
Turcani Peter,
Vachova Marta,
Vecsei Laszlo,
Vodusek David,
Zapletalova Olga,
Berger Thomas
Publication year - 2013
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/cns.12101
Subject(s) - multiple sclerosis , 4 aminopyridine , potassium channel blocker , medicine , clinical practice , physical therapy , physical medicine and rehabilitation , potassium channel , psychiatry
Summary Prolonged‐release fampridine (fampridine PR ) is a potassium channel blocker that improves conductivity of signal on demyelinated axons in central nervous system. Fampridine PR has been approved to improve speed of walking in patients with multiple sclerosis. This statement provides a brief summary of data on fampridine PR and recommendations on practical use of the medication in clinical practice, prediction, and evaluation of response to treatment and patient management.